RecruitingNot ApplicableNCT04184635

Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

Assessment of ECMO in Acute Myocardial Infarction With Non-reversible Cardiogenic Shock to Halt Organ Failure and Reduce Mortality (ANCHOR)

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

400 participants

Start Date

Oct 14, 2021

Study Type

INTERVENTIONAL

Conditions

Cardiogenic Shock Acute Myocardial Infarction

Summary

Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days). An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether ECMO (extracorporeal membrane oxygenation — a machine that temporarily takes over the heart's pumping function) improves survival in patients experiencing cardiogenic shock (when the heart suddenly cannot pump enough blood) during or after a heart attack. **You may be eligible if...** - You are having a heart attack (STEMI or NSTEMI) complicated by cardiogenic shock - Your blood pressure is critically low or requires medication to keep it above a safe level - You have signs of fluid buildup in the lungs and poor blood flow to vital organs - You are being treated with a coronary artery procedure (angioplasty/PCI) **You may NOT be eligible if...** - Your heart failure is from a long-standing condition (not an acute heart attack) - You have severe disease in multiple organs making survival unlikely - You are unable to have blood thinners Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVA-ECMO

* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae. * Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).

Locations(1)

Hôpital Pitié Salpétrière

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04184635

Related Trials

Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

NCT047432451 location

Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure

NCT075271561 location